Thailand

Reimbursed Care Access

Thailand maintains a tightly regulated approach to classical psychedelics: some compounds (notably ketamine) are established in medical practice while others remain scheduled with access limited to research or prohibited outside of strict controls. A 2024 ministerial notification explicitly opened a regulatory pathway for psilocybin research/medical use, but most serotonergic psychedelics (MDMA, DMT, mescaline, 2C-X, etc.) remain controlled with no routine clinical/reimbursed access.